Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 101 entries
Sorted by: Best Match Show Resources per page
Fibrinolytic Activity of Blood and its Determinants in Healthy Medical Students.

Journal of clinical and diagnostic research : JCDR

Siddqui NI, Shoeb M, Bose S.
PMID: 26266114
J Clin Diagn Res. 2015 Jun;9(6):CC05-7. doi: 10.7860/JCDR/2015/12483.6017. Epub 2015 Jun 01.

BACKGROUND: Decreased fibrinolytic activity results in longer fibrinolysis time of blood and an increased propensity for hypercoagulable states of blood. Subjects with less fibrinolytic activity are prone to coronary artery disease, stroke and thromboembolic phenomena.AIM: The study aims to...

Cite
Siddqui NI, Shoeb M, Bose S. Fibrinolytic Activity of Blood and its Determinants in Healthy Medical Students. J Clin Diagn Res. 2015;9(6):CC05-7doi: 10.7860/JCDR/2015/12483.6017.
Siddqui, N. I., Shoeb, M., & Bose, S. (2015). Fibrinolytic Activity of Blood and its Determinants in Healthy Medical Students. Journal of clinical and diagnostic research : JCDR, 9(6), CC05-7. https://doi.org/10.7860/JCDR/2015/12483.6017
Siddqui, Nazeem I, et al. "Fibrinolytic Activity of Blood and its Determinants in Healthy Medical Students." Journal of clinical and diagnostic research : JCDR vol. 9,6 (2015): CC05-7. doi: https://doi.org/10.7860/JCDR/2015/12483.6017
Siddqui NI, Shoeb M, Bose S. Fibrinolytic Activity of Blood and its Determinants in Healthy Medical Students. J Clin Diagn Res. 2015 Jun;9(6):CC05-7. doi: 10.7860/JCDR/2015/12483.6017. Epub 2015 Jun 01. PMID: 26266114; PMCID: PMC4525503.
Copy Download .nbib Format: NLM
Activities of wild-type and variant tissue-type plasminogen activators retained on vascular endothelial cells.

FEBS open bio

Suzuki Y, Sano H, Tomczyk M, Brzoska T, Urano T.
PMID: 27419052
FEBS Open Bio. 2016 Apr 01;6(5):469-76. doi: 10.1002/2211-5463.12057. eCollection 2016 May.

We reported that tissue-type plasminogen activator (tPA) secreted from vascular endothelial cells (VECs) is retained on the cell surface and effectively evokes both plasminogen activation and fibrin clot dissolution (fibrinolysis) on VECs. Here, to evaluate possibly different behaviors of...

Cite
Suzuki Y, Sano H, Tomczyk M, et al. Activities of wild-type and variant tissue-type plasminogen activators retained on vascular endothelial cells. FEBS Open Bio. 2016;6(5):469-76doi: 10.1002/2211-5463.12057.
Suzuki, Y., Sano, H., Tomczyk, M., Brzoska, T., & Urano, T. (2016). Activities of wild-type and variant tissue-type plasminogen activators retained on vascular endothelial cells. FEBS open bio, 6(5), 469-76. https://doi.org/10.1002/2211-5463.12057
Suzuki, Yuko, et al. "Activities of wild-type and variant tissue-type plasminogen activators retained on vascular endothelial cells." FEBS open bio vol. 6,5 (2016): 469-76. doi: https://doi.org/10.1002/2211-5463.12057
Suzuki Y, Sano H, Tomczyk M, Brzoska T, Urano T. Activities of wild-type and variant tissue-type plasminogen activators retained on vascular endothelial cells. FEBS Open Bio. 2016 Apr 01;6(5):469-76. doi: 10.1002/2211-5463.12057. eCollection 2016 May. PMID: 27419052; PMCID: PMC4856425.
Copy Download .nbib Format: NLM
Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1.

Data in brief

Gong L, Liu M, Zeng T, Shi X, Yuan C, Andreasen PA, Huang M.
PMID: 26909366
Data Brief. 2016 Jan 06;6:550-5. doi: 10.1016/j.dib.2015.12.050. eCollection 2016 Mar.

Thrombosis is a leading cause of death worldwide [1]. Recombinant tissue-type plasminogen activator (tPA) is the FDA-approved thrombolytic drug for ischemic strokes, myocardial infarction and pulmonary embolism. tPA is a multi-domain serine protease of the trypsin-family [2] and catalyses...

Cite
Gong L, Liu M, Zeng T, et al. Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1. Data Brief. 2016;6:550-5doi: 10.1016/j.dib.2015.12.050.
Gong, L., Liu, M., Zeng, T., Shi, X., Yuan, C., Andreasen, P. A., & Huang, M. (2016). Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1. Data in brief, 6550-5. https://doi.org/10.1016/j.dib.2015.12.050
Gong, Lihu, et al. "Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1." Data in brief vol. 6 (2016): 550-5. doi: https://doi.org/10.1016/j.dib.2015.12.050
Gong L, Liu M, Zeng T, Shi X, Yuan C, Andreasen PA, Huang M. Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1. Data Brief. 2016 Jan 06;6:550-5. doi: 10.1016/j.dib.2015.12.050. eCollection 2016 Mar. PMID: 26909366; PMCID: PMC4731420.
Copy Download .nbib Format: NLM
Potential for a New Coronary Thrombolytic Plateau.

Journal of thrombosis and thrombolysis

Topol EJ.
PMID: 10602553
J Thromb Thrombolysis. 1996;3(2):127-134. doi: 10.1007/BF00132405.

The GUSTO-I trial provided definitive evidence that early and complete thrombolysis are closely associated with clinical outcome. However, in this trial the best thrombolytic strategy, consisting of accelerated t-PA, aspirin, and heparin, only yielded restoration of brisk flow (TIMI...

Cite
Topol EJ. Potential for a New Coronary Thrombolytic Plateau. J Thromb Thrombolysis. 1996;3(2):127-134doi: 10.1007/BF00132405.
Topol, E. J. (1996). Potential for a New Coronary Thrombolytic Plateau. Journal of thrombosis and thrombolysis, 3(2), 127-134. https://doi.org/10.1007/BF00132405
Topol. "Potential for a New Coronary Thrombolytic Plateau." Journal of thrombosis and thrombolysis vol. 3,2 (1996): 127-134. doi: https://doi.org/10.1007/BF00132405
Topol EJ. Potential for a New Coronary Thrombolytic Plateau. J Thromb Thrombolysis. 1996;3(2):127-134. doi: 10.1007/BF00132405. PMID: 10602553.
Copy Download .nbib Format: NLM
Tissue-type plasminogen activator: characteristics, applications and production technology.

Biotechnology advances

Rouf SA, Moo-Young M, Chisti Y.
PMID: 14537155
Biotechnol Adv. 1996;14(3):239-66. doi: 10.1016/0734-9750(96)00019-5.

Plasminogen activators have immense clinical significance as thrombolytic agents for management of stroke and myocardial infarction. Tissue-type plasminogen activator (tPA) is generally preferred as being effective and safer than either urokinase or streptokinase type activators. Large-scale production of tPA...

Cite
Rouf SA, Moo-Young M, Chisti Y. Tissue-type plasminogen activator: characteristics, applications and production technology. Biotechnol Adv. 1996;14(3):239-66doi: 10.1016/0734-9750(96)00019-5.
Rouf, S. A., Moo-Young, M., & Chisti, Y. (1996). Tissue-type plasminogen activator: characteristics, applications and production technology. Biotechnology advances, 14(3), 239-66. https://doi.org/10.1016/0734-9750(96)00019-5
Rouf, S A, et al. "Tissue-type plasminogen activator: characteristics, applications and production technology." Biotechnology advances vol. 14,3 (1996): 239-66. doi: https://doi.org/10.1016/0734-9750(96)00019-5
Rouf SA, Moo-Young M, Chisti Y. Tissue-type plasminogen activator: characteristics, applications and production technology. Biotechnol Adv. 1996;14(3):239-66. doi: 10.1016/0734-9750(96)00019-5. PMID: 14537155.
Copy Download .nbib Format: NLM
Recombinant plasminogen activators: a comparative review of the clinical pharmacology and therapeutic use of alteplase and reteplase.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Moser M, Kohler B, Schmittner M, Bode C.
PMID: 18020578
BioDrugs. 1998 Jun;9(6):455-63. doi: 10.2165/00063030-199809060-00003.

Thrombolytic therapy has been shown to reduce mortality after acute myocardial infarction. Great efforts have been undertaken in the past decade to develop more efficient thrombolytic regimens. Novel recombinant thrombolytic substances have been engineered. Reteplase, a deletion mutant of...

Cite
Moser M, Kohler B, Schmittner M, et al. Recombinant plasminogen activators: a comparative review of the clinical pharmacology and therapeutic use of alteplase and reteplase. BioDrugs. 1998;9(6):455-63doi: 10.2165/00063030-199809060-00003.
Moser, M., Kohler, B., Schmittner, M., & Bode, C. (1998). Recombinant plasminogen activators: a comparative review of the clinical pharmacology and therapeutic use of alteplase and reteplase. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 9(6), 455-63. https://doi.org/10.2165/00063030-199809060-00003
Moser, M, et al. "Recombinant plasminogen activators: a comparative review of the clinical pharmacology and therapeutic use of alteplase and reteplase." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 9,6 (1998): 455-63. doi: https://doi.org/10.2165/00063030-199809060-00003
Moser M, Kohler B, Schmittner M, Bode C. Recombinant plasminogen activators: a comparative review of the clinical pharmacology and therapeutic use of alteplase and reteplase. BioDrugs. 1998 Jun;9(6):455-63. doi: 10.2165/00063030-199809060-00003. PMID: 18020578.
Copy Download .nbib Format: NLM
Plasminogen activator inhibitors.

Trends in cardiovascular medicine

Schneiderman J, Loskutoff DJ.
PMID: 21239322
Trends Cardiovasc Med. 1991 Apr;1(3):99-102. doi: 10.1016/1050-1738(91)90001-U.

Plasminogen activator inhibitors (PAIs) regulate plasminogen activation in normal and pathologic processes. Plasminogen activator inhibitor 1 (PAI-1) is the major physiologic inhibitor of both tissue-type and urokinase-type plasminogen activators. It is a highly regulated single-chain glycoprotein, whose overexpression in...

Cite
Schneiderman J, Loskutoff DJ. Plasminogen activator inhibitors. Trends Cardiovasc Med. 1991;1(3):99-102doi: 10.1016/1050-1738(91)90001-U.
Schneiderman, J., & Loskutoff, D. J. (1991). Plasminogen activator inhibitors. Trends in cardiovascular medicine, 1(3), 99-102. https://doi.org/10.1016/1050-1738(91)90001-U
Schneiderman, J, and Loskutoff, D J. "Plasminogen activator inhibitors." Trends in cardiovascular medicine vol. 1,3 (1991): 99-102. doi: https://doi.org/10.1016/1050-1738(91)90001-U
Schneiderman J, Loskutoff DJ. Plasminogen activator inhibitors. Trends Cardiovasc Med. 1991 Apr;1(3):99-102. doi: 10.1016/1050-1738(91)90001-U. PMID: 21239322.
Copy Download .nbib Format: NLM
Cellular receptors for plasminogen activators recent advances.

Trends in cardiovascular medicine

Ellis V.
PMID: 21235889
Trends Cardiovasc Med. 1997 Oct;7(7):227-34. doi: 10.1016/S1050-1738(97)00084-4.

The generation of the broad-specificity protease plasmin by the plasminogen activators urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) is implicated in a variety of pathophysiological processes, including vascular fibrin dissolution, extracellular matrix degradation and remodeling, and cell...

Cite
Ellis V. Cellular receptors for plasminogen activators recent advances. Trends Cardiovasc Med. 1997;7(7):227-34doi: 10.1016/S1050-1738(97)00084-4.
Ellis, V. (1997). Cellular receptors for plasminogen activators recent advances. Trends in cardiovascular medicine, 7(7), 227-34. https://doi.org/10.1016/S1050-1738(97)00084-4
Ellis, V. "Cellular receptors for plasminogen activators recent advances." Trends in cardiovascular medicine vol. 7,7 (1997): 227-34. doi: https://doi.org/10.1016/S1050-1738(97)00084-4
Ellis V. Cellular receptors for plasminogen activators recent advances. Trends Cardiovasc Med. 1997 Oct;7(7):227-34. doi: 10.1016/S1050-1738(97)00084-4. PMID: 21235889.
Copy Download .nbib Format: NLM
Successful thrombolysis of a thrombosed prosthetic mitral valve using a synthetic tissue plasminogen activator: a case report.

Journal of medical case reports

Al-Sarraf N, Al-Shammari F, Al-Fadhli J, Al-Shawaf E.
PMID: 20682069
J Med Case Rep. 2010 Aug 03;4:241. doi: 10.1186/1752-1947-4-241.

INTRODUCTION: Prosthetic valve thrombosis is a rare but life-threatening condition that requires careful evaluation and prompt treatment. While surgical intervention remains the gold standard, thrombolytic therapy is now emerging as a potential substitute. Various thrombolytic treatments including streptokinase, urokinase...

Cite
Al-Sarraf N, Al-Shammari F, Al-Fadhli J, et al. Successful thrombolysis of a thrombosed prosthetic mitral valve using a synthetic tissue plasminogen activator: a case report. J Med Case Rep. 2010;4:241doi: 10.1186/1752-1947-4-241.
Al-Sarraf, N., Al-Shammari, F., Al-Fadhli, J., & Al-Shawaf, E. (2010). Successful thrombolysis of a thrombosed prosthetic mitral valve using a synthetic tissue plasminogen activator: a case report. Journal of medical case reports, 4241. https://doi.org/10.1186/1752-1947-4-241
Al-Sarraf, Nael, et al. "Successful thrombolysis of a thrombosed prosthetic mitral valve using a synthetic tissue plasminogen activator: a case report." Journal of medical case reports vol. 4 (2010): 241. doi: https://doi.org/10.1186/1752-1947-4-241
Al-Sarraf N, Al-Shammari F, Al-Fadhli J, Al-Shawaf E. Successful thrombolysis of a thrombosed prosthetic mitral valve using a synthetic tissue plasminogen activator: a case report. J Med Case Rep. 2010 Aug 03;4:241. doi: 10.1186/1752-1947-4-241. PMID: 20682069; PMCID: PMC2922301.
Copy Download .nbib Format: NLM
Metalloproteinases and serine proteases activities in mixed spheroids of mouse b16 melanoma-cells and fibroblasts.

International journal of oncology

Coucke P, Baramova E, Leprince P, Depauwgillet M, Foidart J, Bassleer R.
PMID: 21559690
Int J Oncol. 1994 Nov;5(5):1125-30. doi: 10.3892/ijo.5.5.1125.

A murine B16 melanoma parental line (B16) and two clones either pigmented (B16P) or non-pigmented (B16NP) were cocultured as aggregates with mouse 3T3 fibroblasts. In vivo, these mixed aggregates developed more aggressive tumors in the mouse than corresponding pure...

Cite
Coucke P, Baramova E, Leprince P, et al. Metalloproteinases and serine proteases activities in mixed spheroids of mouse b16 melanoma-cells and fibroblasts. Int J Oncol. 1994;5(5):1125-30doi: 10.3892/ijo.5.5.1125.
Coucke, P., Baramova, E., Leprince, P., Depauwgillet, M., Foidart, J., & Bassleer, R. (1994). Metalloproteinases and serine proteases activities in mixed spheroids of mouse b16 melanoma-cells and fibroblasts. International journal of oncology, 5(5), 1125-30. https://doi.org/10.3892/ijo.5.5.1125
Coucke, P, et al. "Metalloproteinases and serine proteases activities in mixed spheroids of mouse b16 melanoma-cells and fibroblasts." International journal of oncology vol. 5,5 (1994): 1125-30. doi: https://doi.org/10.3892/ijo.5.5.1125
Coucke P, Baramova E, Leprince P, Depauwgillet M, Foidart J, Bassleer R. Metalloproteinases and serine proteases activities in mixed spheroids of mouse b16 melanoma-cells and fibroblasts. Int J Oncol. 1994 Nov;5(5):1125-30. doi: 10.3892/ijo.5.5.1125. PMID: 21559690.
Copy Download .nbib Format: NLM
Proteinases and their inhibitors in liver cancer.

World journal of hepatology

Puxbaum V, Mach L.
PMID: 21160962
World J Hepatol. 2009 Oct 31;1(1):28-34. doi: 10.4254/wjh.v1.i1.28.

Proteinases are known to be involved in many cancer-related processes, particularly in the breakdown of extracellular matrix barriers in the course of tumor invasion and metastasis. In this review we summarize the current knowledge about the role of the...

Cite
Puxbaum V, Mach L. Proteinases and their inhibitors in liver cancer. World J Hepatol. 2009;1(1):28-34doi: 10.4254/wjh.v1.i1.28.
Puxbaum, V., & Mach, L. (2009). Proteinases and their inhibitors in liver cancer. World journal of hepatology, 1(1), 28-34. https://doi.org/10.4254/wjh.v1.i1.28
Puxbaum, Verena, and Mach, Lukas. "Proteinases and their inhibitors in liver cancer." World journal of hepatology vol. 1,1 (2009): 28-34. doi: https://doi.org/10.4254/wjh.v1.i1.28
Puxbaum V, Mach L. Proteinases and their inhibitors in liver cancer. World J Hepatol. 2009 Oct 31;1(1):28-34. doi: 10.4254/wjh.v1.i1.28. PMID: 21160962; PMCID: PMC2998952.
Copy Download .nbib Format: NLM
Purification and characterization of mutant miniPlasmin for thrombolytic therapy.

Thrombosis journal

Lin X, Wang Y, Zhang Y, Huang B, Lin JJ, Hallock SJ, Yu H, Shao H, Yan J, Huang B, Zhang XC, Cao W, Xu X, Lin X.
PMID: 23363549
Thromb J. 2013 Jan 30;11(1):2. doi: 10.1186/1477-9560-11-2.

BACKGROUND: Previous animal studies by us and others have indicated that catheter-administered plasmin or its des-kringle derivatives may be more appropriate alternatives to plasminogen activators for treating thrombolytic diseases, since it has a very short serum half-life and therefore...

Cite
Lin X, Wang Y, Zhang Y, et al. Purification and characterization of mutant miniPlasmin for thrombolytic therapy. Thromb J. 2013;11(1):2doi: 10.1186/1477-9560-11-2.
Lin, X., Wang, Y., Zhang, Y., Huang, B., Lin, J. J., Hallock, S. J., Yu, H., Shao, H., Yan, J., Huang, B., Zhang, X. C., Cao, W., Xu, X., & Lin, X. (2013). Purification and characterization of mutant miniPlasmin for thrombolytic therapy. Thrombosis journal, 11(1), 2. https://doi.org/10.1186/1477-9560-11-2
Lin, Xiaotao, et al. "Purification and characterization of mutant miniPlasmin for thrombolytic therapy." Thrombosis journal vol. 11,1 (2013): 2. doi: https://doi.org/10.1186/1477-9560-11-2
Lin X, Wang Y, Zhang Y, Huang B, Lin JJ, Hallock SJ, Yu H, Shao H, Yan J, Huang B, Zhang XC, Cao W, Xu X, Lin X. Purification and characterization of mutant miniPlasmin for thrombolytic therapy. Thromb J. 2013 Jan 30;11(1):2. doi: 10.1186/1477-9560-11-2. PMID: 23363549; PMCID: PMC3724493.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 101 entries